Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10849956 | XELLIA PHARMS APS | Glycopeptide compositions |
Nov, 2035
(12 years from now) | |
US10188697 | XELLIA PHARMS APS | Glycopeptide compositions |
Nov, 2035
(12 years from now) | |
US10039804 | XELLIA PHARMS APS | Glycopeptide compositions |
Nov, 2035
(12 years from now) | |
US11000567 | XELLIA PHARMS APS | Glycopeptide compositions |
Nov, 2035
(12 years from now) | |
US11517609 | XELLIA PHARMS APS | Glycopeptide compositions |
Nov, 2035
(12 years from now) |
Drugs and Companies using VANCOMYCIN ingredient
Market Authorisation Date: 26 August, 2021
Treatment: Method of treating bacterial infections
Dosage: SOLUTION;INTRAVENOUS, ORAL
9
United States
4
European Union
2
Spain
2
Denmark
2
RS
2
Poland
2
Japan
2
Croatia
2
Portugal
2
Slovenia
2
Hungary
1
Philippines
1
China
1
Brazil
1
Canada
1
Singapore
1
EA
1
Korea, Republic of
1
Chile
1
Israel
1
Mexico
1
Australia
1
Costa Rica
1
South Africa
1
Colombia
1
Saudi Arabia
1
Tunisia
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US11628200 | XELLIA PHARMS APS | Glycopeptide compositions |
Nov, 2035
(12 years from now) | |
US10188697 | XELLIA PHARMS APS | Glycopeptide compositions |
Nov, 2035
(12 years from now) | |
US10039804 | XELLIA PHARMS APS | Glycopeptide compositions |
Nov, 2035
(12 years from now) | |
US10849956 | XELLIA PHARMS APS | Glycopeptide compositions |
Nov, 2035
(12 years from now) | |
US11517609 | XELLIA PHARMS APS | Glycopeptide compositions |
Nov, 2035
(12 years from now) |
Drugs and Companies using VANCOMYCIN HYDROCHLORIDE ingredient
Market Authorisation Date: 15 February, 2019
Treatment: Method of treating bacterial infections
Dosage: SOLUTION;INTRAVENOUS
9
United States
4
European Union
2
Spain
2
Denmark
2
RS
2
Poland
2
Japan
2
Croatia
2
Portugal
2
Slovenia
2
Hungary
1
Philippines
1
China
1
Brazil
1
Canada
1
Singapore
1
EA
1
Korea, Republic of
1
Chile
1
Israel
1
Mexico
1
Australia
1
Costa Rica
1
South Africa
1
Colombia
1
Saudi Arabia
1
Tunisia
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic